Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

´ëº¯ ¹Ì»ý¹°ÃÑ À̽ÄÀÇ ±âÁõÀÚ ¼±º° °Ë»ç Donor Screening for Fecal Microbiota Transplantation

´ëÇѳ»°úÇÐȸÁö 2020³â 95±Ç 3È£ p.181 ~ 187
ÀÌÇÑÈñ, Á¶¿µ¼®,
¼Ò¼Ó »ó¼¼Á¤º¸
ÀÌÇÑÈñ ( Lee Han-Hee ) 
Catholic University College of Medicine Department of Internal Medicine

Á¶¿µ¼® ( Cho Young-Seok ) 
Catholic University College of Medicine Department of Internal Medicine

Abstract


Fecal microbiota transplantation (FMT), which has been established as the standard treatment for recurrent Clostroides difficile infection, may also play a role in the management of other diseases associated with dysbiosis of the gut microbiota. To ensure efficacy and safety of FMT, an appropriate donor screening process is required. The main purpose of donor screening is to check for infectious diseases that could be transmitted to the recipient. The screening process involves a medical history questionnaire, and blood and stool testing. Several randomized clinical trials and large case series on FMT reported no, or few, adverse events related to infection by following this donor screening process. However, there is still concern over the transmission of antibiotic-resistant bacteria. In addition, a low donor acceptance rate due to rigorous screening makes donor recruitment difficult, and also imposes a significant cost burden. A consensus on the most crucial elements of donor screening is needed for wide application of FMT.

Å°¿öµå

Fecal microbiota transplantation; Donor selection; Stool bank

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS